Lantheus to be acquired by Curium for $102.50/share plus up to $12.00 in CVRs

Lantheus Holdings, Inc.

Total consideration up to $114.50/share: $102.50 cash plus CVRs tied to commercial milestones for prostate cancer, neurology, and DEFINITY franchises.
CVR milestones: Global Prostate Cancer Diagnostics sales >$950M triggers $1/share, up to $2/share for >$1.75B.
Transaction expected to close by May 2, 2027, subject to stockholder and regulatory approvals; no financing condition.
Termination fees: Parent pays $385M (or $100M regulatory) to Lantheus; Lantheus pays $228M to Parent.
Board approved $6M transaction bonus pool; $4M to CEO Mary Anne Heino and $500K to CFO Daniel Niedzwiecki, payable at closing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.